Literature DB >> 33958709

Application of targeted nanopore sequencing for the screening and determination of structural variants in patients with Lynch syndrome.

Kiyoshi Yamaguchi1, Rika Kasajima2,3, Kiyoko Takane1, Seira Hatakeyama1, Eigo Shimizu2, Rui Yamaguchi2,4,5, Kotoe Katayama2, Masami Arai6, Chikashi Ishioka6, Takeo Iwama6, Satoshi Kaneko6, Nagahide Matsubara6, Yoshihiro Moriya6, Tadashi Nomizu6, Kokichi Sugano6, Kazuo Tamura6, Naohiro Tomita6, Teruhiko Yoshida6, Kenichi Sugihara6, Yusuke Nakamura7, Satoru Miyano2,8, Seiya Imoto2, Yoichi Furukawa9,10, Tsuneo Ikenoue1.   

Abstract

Lynch syndrome is a hereditary disease characterized by an increased risk of colorectal and other cancers. Germline variants in the mismatch repair (MMR) genes are responsible for this disease. Previously, we screened the MMR genes in colorectal cancer patients who fulfilled modified Amsterdam II criteria, and multiplex ligation-dependent probe amplification (MPLA) identified 11 structural variants (SVs) of MLH1 and MSH2 in 17 patients. In this study, we have tested the efficacy of long read-sequencing coupled with target enrichment for the determination of SVs and their breakpoints. DNA was captured by array probes designed to hybridize with target regions including four MMR genes and then sequenced using MinION, a nanopore sequencing platform. Approximately, 1000-fold coverage was obtained in the target regions compared with other regions. Application of this system to four test cases among the 17 patients correctly mapped the breakpoints. In addition, we newly found a deletion across an 84 kb region of MSH2 in a case without the pathogenic single nucleotide variants. These data suggest that long read-sequencing combined with hybridization-based enrichment is an efficient method to identify both SVs and their breakpoints. This strategy might replace MLPA for the screening of SVs in hereditary diseases.
© 2021. The Author(s), under exclusive licence to The Japan Society of Human Genetics.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33958709     DOI: 10.1038/s10038-021-00927-9

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  1 in total

1.  Quantification of sequence exchange events between PMS2 and PMS2CL provides a basis for improved mutation scanning of Lynch syndrome patients.

Authors:  Heleen M van der Klift; Carli M J Tops; Elsa C Bik; Merel W Boogaard; Anne-Marijke Borgstein; Kerstin B M Hansson; Margreet G E M Ausems; Encarna Gomez Garcia; Andrew Green; Frederik J Hes; Louise Izatt; Liselotte P van Hest; Angel M Alonso; Annette H J T Vriends; Anja Wagner; Wendy A G van Zelst-Stams; Hans F A Vasen; Hans Morreau; Peter Devilee; Juul T Wijnen
Journal:  Hum Mutat       Date:  2010-05       Impact factor: 4.878

  1 in total
  1 in total

Review 1.  Lynch Syndrome and MSI-H Cancers: From Mechanisms to "Off-The-Shelf" Cancer Vaccines.

Authors:  Vladimir Roudko; Cansu Cimen Bozkus; Benjamin Greenbaum; Aimee Lucas; Robert Samstein; Nina Bhardwaj
Journal:  Front Immunol       Date:  2021-09-24       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.